What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce a significant leadership change at The Cigna Group, specifically the appointment of a new Chief Executive Officer and the transition of the current CEO to a new role, along with related compensation and board adjustments. It also serves to reaffirm the company's financial outlook for 2026.

Who is Brian C. Evanko and what is his background?

Brian C. Evanko, age 49, is the incoming CEO of The Cigna Group. He has a strong internal track record with the company, having most recently served as President and Chief Operating Officer since March 2025. Prior to that, he held key financial and leadership roles, including Executive Vice President and Chief Financial Officer, and President of Cigna Healthcare and Government Business segments.

What are the key financial projections being reaffirmed for 2026?

The Cigna Group is reaffirming its projected full-year 2026 consolidated adjusted income from operations of at least $30.25 per share. Additionally, the company is reaffirming its outlook for its key business segments: Evernorth is projected to have at least $6.9 billion in pre-tax adjusted income from operations, and Cigna Healthcare is projected to have at least $4.5 billion in pre-tax adjusted income from operations.

How will David M. Cordani's role change?

David M. Cordani will retire as CEO of The Cigna Group effective July 1, 2026. He will transition to the role of Executive Chair of the Board, effective the same date. His compensation package has been adjusted to reflect this new role, including a base salary of $1 million and an EIP target of $2 million, with continued eligibility for LTI awards.

CI 8-K: Leadership Changes & Regulation FD

Summary

The Cigna Group announced a significant leadership transition through an 8-K filing on March 3, 2026. Effective July 1, 2026, Brian C. Evanko will assume the role of Chief Executive Officer, succeeding David M. Cordani, who will transition to Executive Chair of the Board. This move signifies an internal promotion for Mr. Evanko, who has held various senior leadership positions within the company, including President and Chief Operating Officer. The filing also detailed Mr. Evanko's new compensation package, which includes a base salary of $1.3 million, an Enterprise Incentive Plan target of $2.6 million, and a Long-Term Incentive target of $15.1 million, along with a one-time transitional equity award. In addition to the CEO succession, Cigna Group reaffirmed its full-year 2026 financial outlook, projecting consolidated adjusted income from operations of at least $30.25 per share. The company also reiterated specific outlooks for its Evernorth and Cigna Healthcare segments. The filing also noted board composition changes, including Mr. Evanko's election to the Board and Mr. Eric J. Foss's appointment as Lead Independent Director, effective April 1, 2026.

Key Highlights

1Brian C. Evanko appointed Chief Executive Officer, effective July 1, 2026, succeeding David M. Cordani.
2David M. Cordani to transition from CEO to Executive Chair of the Board, effective July 1, 2026.
3Mr. Evanko's new CEO compensation includes a $1.3M base salary, $2.6M EIP target, and $15.1M LTI target, plus a $3.5M transitional equity award.
4The Board size was increased to twelve members, and Mr. Evanko was elected as a director, effective April 1, 2026.
5Eric J. Foss elected Lead Independent Director, effective April 1, 2026, succeeding Eric C. Wiseman.
6Cigna Group reaffirms its full-year 2026 consolidated adjusted income from operations outlook of at least $30.25 per share.
72026 outlook reaffirmed for Evernorth (at least $6.9 billion pre-tax adjusted income) and Cigna Healthcare (at least $4.5 billion pre-tax adjusted income).

Cigna Group 8-K Report, Executive Changes (Mar 3, 2026)

Summary

Key Highlights

Frequently Asked Questions